Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

What's In Store For Science Applications' (SAIC) Q4 Earnings?

Published 03/25/2020, 07:33 AM
Updated 07/09/2023, 06:31 AM

Science Applications International Corporation (NYSE:SAIC) is set to report fourth-quarter fiscal 2020 results on Mar 26.

The company’s earnings surpassed the Zacks Consensus Estimate in three of the last four quarters and missed in the other, the average positive surprise being 11.7%.

In the last reported quarter, the company delivered earnings of $1.39 per share, missing the Zacks Consensus Estimate of $1.44. However, the bottom-line figure improved nearly 3% year over year. Moreover, revenues jumped 38% from the year-ago quarter to $1.6 billion but lagged the Zacks Consensus Estimate of $1.63 billion.

The Zacks Consensus Estimate for fiscal fourth-quarter revenues is pegged at $1.57 billion, indicating approximately 32% improvement from the year-ago reported figure. For earnings, the consensus estimate stands at $1.32, suggesting 12.8% year-over-year growth.

Let’s see how things are shaping up prior to this announcement.

Factors to Consider

Science Applications’ fiscal fourth-quarter performance is likely to have benefited from its strong product portfolio, which is aiding contract wins. The company’s capability to sustain its existing contracts, coupled with the newly-awarded ones across the customer portfolio, is likely to have been a steady tailwind.

Moreover, the integration of the Engility buyout might have driven the company’s top and bottom lines. In the last reported quarter, excluding Engility, revenues dipped 1.5%, year on year.

The acquisition of Engility is also likely to have boosted the company’s margin profile and cash flow.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Nonetheless, revenue dis-synergies due to the elimination of prime sub-duplicate revenues might have had a slight negative impact. Further, higher interest expenses are likely to have dampened the bottom line.

Furthermore, investors should be more focused on the company’s guidance rather than the quarterly results. Science Applications’ guidance for fiscal 2021 will give a proper insight about the company’s plans to combat the coronavirus crisis and stay afloat.

What Our Model Says

Our proven model does not predict an earnings beat for Science Applications this season. The combination of a positive Earnings ESP, and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell, before they’re reported, with our Earnings ESP Filter.

Science Applications currently carries a Zacks Rank of 2 and has an Earnings ESP of -0.51%.

Stocks to Consider

Here are some companies, which, per our model, have the right combination of elements to post an earnings beat in their soon to be reported quarterly results:

FactSet Research Systems Inc. (NYSE:FDS) has an Earnings ESP of +0.77% and carries a Zacks Rank of 2, at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Ascendis Pharma A/S (NASDAQ:ASND) has an Earnings ESP of +3.15% and carries a Zacks Rank of 3, at present.

Lululemon Athletica Inc. (NASDAQ:LULU) has an Earnings ESP of +0.42% and currently carries a Zacks Rank of 3.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>



lululemon athletica inc. (LULU): Free Stock Analysis Report

FactSet Research Systems Inc. (FDS): Free Stock Analysis Report

Science Applications International Corporation (SAIC): Free Stock Analysis Report

Ascendis Pharma A/S (ASND): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.